D. Aufauvre

[Quality of life and multiple sclerosis: validation of the french version of the self-questionnaire (SEP-59)].

J. Coste, L. Gerbaud, D. Vernay, 2000, Revue neurologique.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

D. Yarnitsky, M. Valis, H. Hartung, 2019, Journal of the peripheral nervous system : JPNS.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

G. L. Masson, D. Yarnitsky, S. Muley, 2018, The Lancet Neurology.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

G. L. Masson, D. Yarnitsky, M. Valis, 2019, Journal of the peripheral nervous system : JPNS.

[Validation of the combined SF36/MSQOL test of evaluation of quality of life in migraine patients in France].

B. Laurent, P. Preux, L. Gerbaud, 2002, Revue neurologique.

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.

C. Louapre, S. Vukusic, C. Mékiès, 2019, Revue neurologique.